


1/15



MAb B5 positive





Fig. 1

2/15

*N. meningitidis* LPS**Fig. 2**

3/15




Fig. 3

10/089583

PCT/GB00/03758

WO 01/22994

4/15




Fig .4
N. meningitidis LPS

5/15







Fig. 5

6/15




Fig. 6

7/15




Fig. 7

8/15




Fig. 8

9/15

STRATEGY DIAGRAM
(Methods used in brackets)

↓

Identify antibody accessible epitopes of wild-type encapsulated Gp B Nm strains (2,3,4) ↓

Investigate conservation of antibody accessible inner core epitopes in natural population of Nm (3) ↓

Investigate the structure of LPS derived from Nm of known mab reactivity (5) ↓

Define details of conserved antibody accessible epitopes (2,5) ↓

Select minimum number of glycoforms having range of epitopes representative of all Nm strains (3,4,5) ↓

Investigate potential of glycoform to elicit functional antibodies (e.g bacterial, opsonophagcytic & animal protection assays)

Fig. 9

10/15




Fig. 10a




Fig. 10b




Fig. 11a




Fig. 11b




Fig. 11c

12/15




Fig. 12

13/15




Fig. 13

14/15




Fig. 14

15/15




Fig. 15